Watson Laboratories has received important FDA approval for an abbreviated new drug application (ANDA040171), paving the way for the entry of a 1997-vintage generic into the market with potential market implications; however, without a specific active pharmaceutical ingredient or generic name, current investors cannot assess the exact revenue impact.